3-V Biosciences snags $28.5 mln Series D

Menlo Park, Calif.-based biopharmaceutical firm 3-V Biosciences has closed $28.5 million in Series D funding. New Enterprise Associates, Kleiner Perkins Caufield & Byers and Rock Springs Capital Management led the round with participation from other investors that included Ally Bridge Group.

North AmericaUSBriefs